Integrated analysis of HER2 copy number by cytogenomic microarray in breast cancers with nonclassical in situ hybridization results

Gloria T. Haskell, Yajuan J. Liu, Hui Chen, Beiyun Chen, Reid G. Meyer, Jason A. Yuhas, Katherine B. Geiersbach

Research output: Contribution to journalArticle

Abstract

Objectives: To develop and test an integrated approach to human epidermal growth factor receptor 2 (HER2) copy number analysis in breast cancer using in situ hybridization (ISH) and cytogenomic microarray (CMA). Methods: CMA was performed on four clinical breast cancer samples with nonclassical patterns of HER2 ISH results. Integrated analysis was performed by correlating the data from pathology review, ISH, and CMA. Results: Integrated analysis provided a more comprehensive view of the genomic copy number landscape that informed HER2 copy number analysis, but ISH provided essential data in all cases. Conclusions: CMA can be helpful for clarifying HER2 amplification status in breast cancer. However, uncertainties over tumor percentage, clonal heterogeneity, and varying ploidy levels present challenges for genomic methods such as CMA. Accurate interpretation of HER2 copy number by CMA requires correlation with the pathology and ISH data.

Original languageEnglish (US)
Pages (from-to)135-147
Number of pages13
JournalAmerican Journal of Clinical Pathology
Volume149
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

In Situ Hybridization
Breast Neoplasms
Pathology
Ploidies
Uncertainty
human ERBB2 protein
Neoplasms

Keywords

  • Breast cancer
  • Copy number
  • HER2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Integrated analysis of HER2 copy number by cytogenomic microarray in breast cancers with nonclassical in situ hybridization results. / Haskell, Gloria T.; Liu, Yajuan J.; Chen, Hui; Chen, Beiyun; Meyer, Reid G.; Yuhas, Jason A.; Geiersbach, Katherine B.

In: American Journal of Clinical Pathology, Vol. 149, No. 2, 01.02.2018, p. 135-147.

Research output: Contribution to journalArticle

Haskell, Gloria T. ; Liu, Yajuan J. ; Chen, Hui ; Chen, Beiyun ; Meyer, Reid G. ; Yuhas, Jason A. ; Geiersbach, Katherine B. / Integrated analysis of HER2 copy number by cytogenomic microarray in breast cancers with nonclassical in situ hybridization results. In: American Journal of Clinical Pathology. 2018 ; Vol. 149, No. 2. pp. 135-147.
@article{c4cc9d88e4124ffebc3c7c01efce6a59,
title = "Integrated analysis of HER2 copy number by cytogenomic microarray in breast cancers with nonclassical in situ hybridization results",
abstract = "Objectives: To develop and test an integrated approach to human epidermal growth factor receptor 2 (HER2) copy number analysis in breast cancer using in situ hybridization (ISH) and cytogenomic microarray (CMA). Methods: CMA was performed on four clinical breast cancer samples with nonclassical patterns of HER2 ISH results. Integrated analysis was performed by correlating the data from pathology review, ISH, and CMA. Results: Integrated analysis provided a more comprehensive view of the genomic copy number landscape that informed HER2 copy number analysis, but ISH provided essential data in all cases. Conclusions: CMA can be helpful for clarifying HER2 amplification status in breast cancer. However, uncertainties over tumor percentage, clonal heterogeneity, and varying ploidy levels present challenges for genomic methods such as CMA. Accurate interpretation of HER2 copy number by CMA requires correlation with the pathology and ISH data.",
keywords = "Breast cancer, Copy number, HER2",
author = "Haskell, {Gloria T.} and Liu, {Yajuan J.} and Hui Chen and Beiyun Chen and Meyer, {Reid G.} and Yuhas, {Jason A.} and Geiersbach, {Katherine B.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/AJCP/AQX143",
language = "English (US)",
volume = "149",
pages = "135--147",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Integrated analysis of HER2 copy number by cytogenomic microarray in breast cancers with nonclassical in situ hybridization results

AU - Haskell, Gloria T.

AU - Liu, Yajuan J.

AU - Chen, Hui

AU - Chen, Beiyun

AU - Meyer, Reid G.

AU - Yuhas, Jason A.

AU - Geiersbach, Katherine B.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objectives: To develop and test an integrated approach to human epidermal growth factor receptor 2 (HER2) copy number analysis in breast cancer using in situ hybridization (ISH) and cytogenomic microarray (CMA). Methods: CMA was performed on four clinical breast cancer samples with nonclassical patterns of HER2 ISH results. Integrated analysis was performed by correlating the data from pathology review, ISH, and CMA. Results: Integrated analysis provided a more comprehensive view of the genomic copy number landscape that informed HER2 copy number analysis, but ISH provided essential data in all cases. Conclusions: CMA can be helpful for clarifying HER2 amplification status in breast cancer. However, uncertainties over tumor percentage, clonal heterogeneity, and varying ploidy levels present challenges for genomic methods such as CMA. Accurate interpretation of HER2 copy number by CMA requires correlation with the pathology and ISH data.

AB - Objectives: To develop and test an integrated approach to human epidermal growth factor receptor 2 (HER2) copy number analysis in breast cancer using in situ hybridization (ISH) and cytogenomic microarray (CMA). Methods: CMA was performed on four clinical breast cancer samples with nonclassical patterns of HER2 ISH results. Integrated analysis was performed by correlating the data from pathology review, ISH, and CMA. Results: Integrated analysis provided a more comprehensive view of the genomic copy number landscape that informed HER2 copy number analysis, but ISH provided essential data in all cases. Conclusions: CMA can be helpful for clarifying HER2 amplification status in breast cancer. However, uncertainties over tumor percentage, clonal heterogeneity, and varying ploidy levels present challenges for genomic methods such as CMA. Accurate interpretation of HER2 copy number by CMA requires correlation with the pathology and ISH data.

KW - Breast cancer

KW - Copy number

KW - HER2

UR - http://www.scopus.com/inward/record.url?scp=85044504282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044504282&partnerID=8YFLogxK

U2 - 10.1093/AJCP/AQX143

DO - 10.1093/AJCP/AQX143

M3 - Article

C2 - 29385416

AN - SCOPUS:85044504282

VL - 149

SP - 135

EP - 147

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -